- Home
- CRMD vs IMNM Comparison
CRMD vs IMNM Comparison
Compare CRMD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- IMNM
- Stock Information
- Founded
- CRMD 2006
- IMNM 2006
- Country
- CRMD United States
- IMNM United States
- Employees
- CRMD N/A
- IMNM N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CRMD Health Care
- IMNM Health Care
- Exchange
- CRMD Nasdaq
- IMNM Nasdaq
- Market Cap
- CRMD 925.6M
- IMNM 945.8M
- IPO Year
- CRMD 2010
- IMNM 2020
- Fundamental
- Price
- CRMD $12.94
- IMNM $9.21
- Analyst Decision
- CRMD Strong Buy
- IMNM Strong Buy
- Analyst Count
- CRMD 8
- IMNM 8
- Target Price
- CRMD $17.57
- IMNM $24.75
- AVG Volume (30 Days)
- CRMD 4.6M
- IMNM 1.0M
- Earning Date
- CRMD 10-29-2025
- IMNM 11-12-2025
- Dividend Yield
- CRMD N/A
- IMNM N/A
- EPS Growth
- CRMD N/A
- IMNM N/A
- EPS
- CRMD 0.79
- IMNM N/A
- Revenue
- CRMD $121,484,498.00
- IMNM $12,589,000.00
- Revenue This Year
- CRMD $404.81
- IMNM N/A
- Revenue Next Year
- CRMD $56.11
- IMNM $154.73
- P/E Ratio
- CRMD $16.35
- IMNM N/A
- Revenue Growth
- CRMD 14970.29
- IMNM 16.74
- 52 Week Low
- CRMD $5.60
- IMNM $5.15
- 52 Week High
- CRMD $17.43
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- CRMD 49.60
- IMNM 44.56
- Support Level
- CRMD $12.73
- IMNM $8.67
- Resistance Level
- CRMD $13.83
- IMNM $10.65
- Average True Range (ATR)
- CRMD 0.75
- IMNM 0.70
- MACD
- CRMD -0.16
- IMNM -0.07
- Stochastic Oscillator
- CRMD 40.24
- IMNM 27.46
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.